Eli Lilly vies to join $1trn stock market club with Zepbound weight loss drug 

Zepbound, which was recently approved for weight loss, is predicted to become the best-selling drug in history

Eli Lilly’s market capitalisation is at $719bn, placing it among the 10 most valuable companies in the S&P 500 Index in the US.

Eli Lilly's relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of the "Magnificent Seven" to reach a market value of $1trn. 

The analysts lifted their price target on the weight-loss drugmaker to the highest on Friday, to a level that would take the market capitalisation to about $900bn (€836bn).